Cancer stemness meets immunity: from mechanism to therapy
Cancer stem cells (CSCs) are self-renewing cells that facilitate tumor initiation, promote
metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many …
metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many …
Monocyte-neutrophil entanglement in glioblastoma
D Friedmann-Morvinski… - The Journal of clinical …, 2023 - Am Soc Clin Investig
Glioblastoma (GBM) is the most belligerent and frequent brain tumor in adults. Research
over the past two decades has provided increased knowledge of the genomic and molecular …
over the past two decades has provided increased knowledge of the genomic and molecular …
Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression
Glioblastoma (GBM), a highly lethal brain cancer, is notorious for immunosuppression, but
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …
[HTML][HTML] Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review
M Lecoultre, V Dutoit, PR Walker - Journal for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Tumor-associated macrophage (TAM) phagocytic activity is emerging as a new mechanism
to harness for cancer treatment. Currently, many approaches are investigated at the …
to harness for cancer treatment. Currently, many approaches are investigated at the …
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment
J Wen, S Wang, R Guo, D Liu - European Journal of Medicinal Chemistry, 2023 - Elsevier
Abstract ABSTRACT: Colony-Stimulating Factor-1 Receptor (CSF1R) is a receptor tyrosine
kinase that controls the differentiation and maintenance of most tissue-resident …
kinase that controls the differentiation and maintenance of most tissue-resident …
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models
M Datta, S Chatterjee, EM Perez… - Proceedings of the …, 2023 - National Acad Sciences
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we
found that ICBs induce cerebral edema in some patients and mice with glioblastoma …
found that ICBs induce cerebral edema in some patients and mice with glioblastoma …
Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy
RS Andersen, A Anand, DSL Harwood, BW Kristensen - Cancers, 2021 - mdpi.com
Simple Summary Patients with glioblastoma—the most frequent and malignant primary brain
tumor—have a poor prognosis with a median survival of less than 15 months. Despite …
tumor—have a poor prognosis with a median survival of less than 15 months. Despite …
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
KJ Habashy, R Mansour, C Moussalem… - British journal of …, 2022 - nature.com
Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …
Circadian regulator CLOCK drives immunosuppression in glioblastoma
The symbiotic interactions between cancer stem cells and the tumor microenvironment
(TME) are critical for tumor progression. However, the molecular mechanism underlying this …
(TME) are critical for tumor progression. However, the molecular mechanism underlying this …
Tumor-associated macrophage-related strategies for glioma immunotherapy
F Tang, Y Wang, Y Zeng, A Xiao, A Tong… - NPJ precision oncology, 2023 - nature.com
High-grade glioma is one of the deadliest primary tumors of the central nervous system.
Despite the many novel immunotherapies currently in development, it has been difficult to …
Despite the many novel immunotherapies currently in development, it has been difficult to …